Access, SpePharm in European MuGard pact
This article was originally published in Clinica
Dallas, Texas-based Access Pharmaceuticals has signed an agreement which will see its oral wound rinse product MuGard marketed in Europe by Dutch company SpePharm. The agreement incorporates the European Union plus Switzerland, Norway and Iceland, and will see SpePharm become responsible for manufacturing and regulatory approval of the product within this territory.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.